Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

Brian has Fabry disease, a lysosomal storage disorder that can cause a variety of symptoms. “It's a condition where your cells are not able to break down a certain substance, and that ...

4D-310 is under development for the treatment of Fabry disease. The drug candidate is administered through intravenous route. The drug candidate is based on vector evolution platform technology that ...

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a ...

Amicus Therapeutics' shares are down 15% recently despite a profitable Q3 2024 and raised FY2024 outlook. Click here to find ...

Major positive events in 2024 include India’s first solar-powered remote village, the discovery of plastic-decomposing worms, ...

"We are committed to delivering innovative therapies and solutions for people living with Fabry disease, their families and caregivers." A biopharmaceutical company, Protalix leverages its plant ...